other material
confidence high
sentiment positive
materiality 0.85
Sagimet reports positive Phase 2b NASH trial: denifanstat meets primary endpoints with statistical significance
Sagimet Biosciences Inc.
- NASH resolution without worsening fibrosis (≥2-point NAS reduction): 36% denifanstat vs 13% placebo (p=0.0022).
- Fibrosis improvement ≥1 stage without NASH worsening: 41% denifanstat vs 18% placebo (p=0.0051).
- MRI-PDFF ≥30% reduction: 65% denifanstat vs 21% placebo (p<0.0001).
- No treatment-related SAEs; discontinuation rate 19.6% denifanstat vs 5.4% placebo.